Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Lee430on Sep 23, 2024 5:17pm
42 Views
Post# 36237217

RE:A few weeks to find a fix

RE:A few weeks to find a fixWhat happens if the FDA does not give it’s blessing to the next batch of EGRIFTA SV due to reasons behind the manufacturing concerns that caused this shutdown?

Trogarzon wrote: Probably working on a fix for the supplier/FDA nightmare before the Q3 call.  It's all about forward looking news from there on.  Hopefully it doesn't cause more dilution and or ongoing concern drama.  Everytime somekind of positive trends sets in they come up with some dreadfull unforseen event like this. Like others mentioned you can can't be this unlucky, it's incompetence.  Also, once again it's communicated in terrible way by people who don't understand human psychology.  


<< Previous
Bullboard Posts
Next >>